Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Johnson and Johnson
Baxter
Merck
McKinsey

Last Updated: July 4, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Voxilaprevir


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Voxilaprevir?

Voxilaprevir is an investigational drug.

There have been 13 clinical trials for Voxilaprevir. The most recent clinical trial was a Phase 2 trial, which was initiated on November 18th 2018.

The most common disease conditions in clinical trials are Hepatitis C, Infection, and Virus Diseases. The leading clinical trial sponsors are Gilead Sciences, University of Maryland, and National Institutes of Health (NIH).

There are twenty-seven US patents protecting this investigational drug and seven hundred and one international patents.

Recent Clinical Trials for Voxilaprevir
TitleSponsorPhase
Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV InfectionGilead SciencesPhase 3
Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3)Partners in HealthPhase 4
Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvirKirby InstitutePhase 4

See all Voxilaprevir clinical trials

Clinical Trial Summary for Voxilaprevir

Top disease conditions for Voxilaprevir
Top clinical trial sponsors for Voxilaprevir

See all Voxilaprevir clinical trials

US Patents for Voxilaprevir

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Voxilaprevir   Start Trial Synthesis of an antiviral compound GILEAD SCIENCES, INC. (Foster City, CA)   Start Trial
Voxilaprevir   Start Trial Combination formulation of two antiviral compounds Gilead Pharmasset LLC (Foster City, CA)   Start Trial
Voxilaprevir   Start Trial Toll like receptor modulator compounds GILEAD SCIENCES, INC. (Foster City, CA)   Start Trial
Voxilaprevir   Start Trial Inhibitors of hepatitis C virus Gilead Pharmasset LLC (Foster City, CA)   Start Trial
Voxilaprevir   Start Trial Toll like receptor modulator compounds GILEAD SCIENCES, INC. (Foster City, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Voxilaprevir

Drugname Country Document Number Estimated Expiration Related US Patent
Voxilaprevir Argentina 098959 2033-12-23   Start Trial
Voxilaprevir Australia 2014370125 2033-12-23   Start Trial
Voxilaprevir Canada 2934537 2033-12-23   Start Trial
Voxilaprevir China 105849118 2033-12-23   Start Trial
Voxilaprevir Eurasian Patent Organization 201691031 2033-12-23   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Baxter
AstraZeneca
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.